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Introduction. A comparison of the cost of an alternative treatment regimen is the basis of the rationalisation and 
cost effectiveness of cancer therapy. The aim of the study was to compare two alternative treatment regimens for 
colorectal cancer in the III and IV advancement stage (FOLFOX4 and XELOX). 
Material and methods. A cost-effectiveness analysis was carried out on the basis of data collected retrospectively; 
considering 100 patients treated at the Oncology Centre in Bydgoszcz. A measure of the effectiveness of the therapy was 
the total survival time of patients. Data on the average survival time of patients has been obtained from clinical trials. 
Results. The total cost of treatment per patient was 33 879.13 PLN in FOLFOX4. In XELOX the average cost per patient 
was 20 023.96 PLN. The endpoint, defined as the average survival time of patients treated with the FOLFOX4 scheme 
amounted to 27.25 months. In the case of the use of the XELOX regimen, the average survival time was 23.65 months. 
Incremental costs for additional units as a result of using the more expensive treatment regimen were estimated as 
46 183.47 PLN. 
Conclusions. The comparison of the two treatment regimens for colorectal cancer in stage III and IV, which were used 
in the Oncology Centre in Bydgoszcz, showed that the more expensive but more efficient treatment was FOLFOX4.
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Introduction 
Colorectal cancer belongs to a group of cancers with 
increasing frequency of incidence in Poland and in other 
highly developed countries. Epidemiological data indicate 
an increasing incidence and mortality with age, both among 
men and women [1].
The basic method of treatment of colorectal cancer, 
especially in its early stages is surgical intervention. This 
concerns rectal cancer in particular, as the efficiency of 
other methods has not been proven [2]. The resection scope 
depends on the tumour location, vascularisation of the af-
fected area and the advancement stage [3, 4].
In spite of the domination of surgery in the treatment 
of colorectal cancer, the application of adjuvant chemo-
therapy (regimens based on 5-fluorouracil, calcium foli-
nate or disodium folinate, capecitabin and oxaliplatin) has 
a significant influence on increasing the 5-year survival 
period and future disease-free survival. Pharmacological 
treatment of the cancer may also be a neo-adjuvant (alone 
or in combination with radiotherapy) or palliative treatment. 
Drug regimens may also contain irinotecan, bevacizumab 
and cetuximab [1].
In recent years in foreign centres, some pharmacokinetic 
analyses have been performed comparing various drug 
regimens in the treatment of colorectal cancers [5–8]. The 
results of these analyses point to the fact that the most 
cost-effective regimen is XELOX. It must be stressed, how-
ever, that with regards to the varied financial situation of 
the health service and diversified drug prices, as well as 
differences in the approach of the public payer, it is diffi-
cult to compare the results of the pharmacokinetic studies 
performed abroad with the situation in Poland.
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The objective of this paper is to perform a retrospective 
comparison of the costs and effects of chemotherapy based 
on the FOLFOX4 and XELOX regimens, applied in colorectal 
cancer patients with advancement stage III and IV at the F. 
Łukaszczyk Oncology Centre in Bydgoszcz.
The analysis allowed to determinate how the cost was 
distributed in the applied treatment regimen and to show 
which regimen proposes a better method of treatment in 
the aspect of costs and benefits.
Materials and methods 
The retrospective analysis comprised the documents 
of 100 patients treated in the outpatient clinic and hospi-
tal of the F. Łukaszczyk Oncology Centre in Bydgoszcz in 
2008–2011. The inclusion criteria were: treatment at the On-
cology Centre in Bydgoszcz, histopathologically confirmed 
diagnosis, advancement stage III and IV, performed surgery 
and the application of the first line of chemotherapy with 
the FOLFOX4 regimen (60 patients) or XELOX regimen (40 
patients). The data characterising the patients are presented 
in Table I.
The study comprised the analysis of the cost efficiency 
carried out in accordance with the guidelines of the Good 
Pharmacoeconomic Practice. The criterion for the evaluation 
of the treatment efficiency was the average survival period. 
The study was performed from the perspective of a payer. 
The evaluation of the drug prices is based on the data from 
November 2014.
In both studied treatment regimens, the following types 
of treatment costs were taken into consideration: hospitali-
sation, outpatient treatment, diagnostic procedures, costs 
of cytostatic drugs and their preparation, the costs of other 
medication including the alleviation of adverse events and 
haematological complications, radiotherapy and consulta-
tion costs.
Results 
Hospitalisation costs 
The hotel costs, duration of hospital stays and the costs 
of one-day hospitalisation are displayed in Table II. This 
analysis takes into consideration the costs of the hospitali-
sation resulting from the treatment of the primary disease, 
diagnostic tests, adverse effects of the medication and the 
deterioration of the patients’ general condition. Treatment 
on the outpatient basis was carried out in the case of pa-
tients in good general condition with a good tolerance of 
chemotherapy or in the case of lack of vacancies in the 
hospital ward.
The total hospital stay in patients treated with the 
FOLFOX4 regimen was 2201 days, which gives an average 
amount of 36.7 days per patient with an average cost of 
20 439 PLN. The aggregate duration of the hospital stay for 
those patients treated with the XELOX regimen was 443 
days, which gives 11.08 days per patient on average with 
the mean cost of 6186.7 PLN.
The one-day hospitalisation period in the FOLFOX4 
group was 71 days in total with the mean value per patient 
being 1.18 days and the average costs of 553.8 PLN; in the 
XELOX group — it was 265 and 6.63 days respectively with 
the average cost being 3219.7 PLN. The costs of outpatient 
hospitalisation were calculated according to the rate stipu-
lated in the contracts with the National Health Fund, that 
is 468 PLN per patient. The cost difference in the case of 
one-day hospitalisation between the analysed treatment 
regimens is significant and amounts to 95 562 PLN in total 
and, calculated per patient, is 2665.95 PLN. The higher cost 
of one-day hospitalisation is generated by the XELOX regi-
men, which is the outcome of the outpatient character of 
this programme.
The costs of diagnostic tests
The costs of diagnostic tests were divided into two 
groups: laboratory tests and imaging tests (Tab. II). Out of 
the laboratory tests, the most frequent ones comprised the 
levels of the liver enzymes — creatinine and urea. Also CBC 
and CBC with differentials as well as the neutrophil absolute 
count were performed.
Table I. Patients’ characteristics 
Treatment protocol FOLFOX4 XELOX
The number of patients  
in advancement stage III
33 23
The number of patients  
in advancement stage IV
27 17
Mean age of the patients 60.43 60.88
Men 30 24
Women 30 16
Table II. Hospitalisation (H) and outpatient (A) duration and costs 
Protocol Duration of stay (days) Cost (PLN)
Total Average Total Average 
H A H A H A H A
FOLFOX4 2201 71 36.68 1.18 1 226 368 33 228 20 439.47 553.8
XELOX 443 265 11.08 6.63 247 468 128 790 6186.7 3219.75
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The most frequent imaging tests in both groups of pa-
tients comprised: an abdominal ultrasound, P-A and lateral 
chest X-ray and histopathology. 
Higher cost of diagnostic procedures is generated by 
the FOLFOX4 regimen. The difference between the analysed 
groups was 70 624.6 PLN, and, per one patient the differ-
ence amounted to 212 PLN. The higher cost of diagnostic 
procedures on the FOLFOX4 group was the result of the 
more frequent performance of tests such as CBC, CBC with 
differential, and costly examinations such as a colonoscopy 
or plain and contrast abdominal CT .
Medication costs 
The constituents of the pharmacotherapy were the costs 
of the first line chemotherapy, the costs of consecutive lines 
of chemotherapy in the case of the failure of the first line, 
the costs of cytostatic drug preparation, the costs of gas-
troprotective medication (most frequently: ondansetron, 
metoclopramide and ornithine), infusion liquids, analgesic 
and psychotropic drugs as well as other medication.
Patients treated with the FOLFOX4 regimen, on the first 
day of therapy received oxaliplatin in a dose of 85 mg/m2, 
calcium folinate in a dose of 200 mg/m2 on the first and 
second day in 2-hour infusions and fluorouracil in a dose 
of 400 mg/m2 in a bolus on day 1 and then 600 mg/m2 in 
a 22-hour infusion on days 1 and 2. The treatment lasted 6 
months in 12 cycles every 2 weeks.
In the XELOX group, capecitabin p.o. was administered in 
a dose of 1000 mg/m2, twice per day for 14 days and oxali-
platin in a dose of 130 mg/m2 i.v. on day 1. The cycles were 
repeated every 3 weeks. The treatment lasted 6 months. 
The symptoms of significant drug toxicity, lack of re-
sponse to cytostatic treatment as well as disease progression 
or relapse were quite frequently observed in these patients. 
In such cases, a second line of chemotherapy, and, in the 
case of the lack of improvement, some other cytostatic drugs 
were administered.
In both patient groups, the most frequently adminis-
tered medication in consecutive lines of chemotherapy 
were the CLF1 regimen (irinotecan, fluorouracil and calcium 
folinate) and the LF4 regimen (fluorouracil in i.v. infusion 
and fluorouracil i.v. bolus in combination with calcium fo-
linate). Table III presents the costs of pharmacotherapy in 
the analysed groups.
Cytostatic drugs have the largest share in total medica-
tions costs.
Costs of treatment for haematological 
complications
One of the most frequent haematological complications 
in chemotherapy is neutropenia. Therefore, filgastrim was 
often applied in the FOLFOX4 group. In the XELOX group, 
incidences of severe anaemia was observed. Then the pa-
tients received transfusions of PRBC.
The total cost of treatment for haematological complica-
tions was calculated by means of summing up the cost of 
the medication used for the treatment of neutropenia and 
anaemia. This cost is almost twice as high as calculated per 
patient in the XELOX group. The difference results mostly 
from the application of PRBC.
Radiotherapy costs
In both patient groups, palliative and preoperative (as 
a constituent of radical treatment) radiotherapy was used. 
In FOLFOX4, radiotherapy was used in 13 patients, and in 
6 cases it was preoperative radiotherapy whilst in 6 other 
patients — palliative. One patient received both types of 
irradiation.
Radiotherapy in the XELOX group was applied jointly 
in 3 cases, and in 2 patients it was a radical preoperative 
radiotherapy and in 1 case, radiotherapy had a palliative 
character.
The total cost of radiotherapy in the FOLFOX4 group 
amounted to 82 368 PLN, which makes 1372.8 PLN per 
Table III. The cost of medication in the studied groups 
Source of the cost Cost (PLN)
FOLFOX4 XELOX
Total cost Average cost per 1 patient % Total cost Average cost per 1 patient %
Chemotherapy 448 201.5 7470.05 99.4 256 401.3 6410.03 99.16
Analgesic drugs 1419.87 23.66 0.27 1160.45 29.01 0.45
Drugs affecting GI tract 154.18 2.57 0.03 28.77 0.72 0.006
Drugs affecting circulatory 721.01 12.02 0.14 468.59 11.71 0.11
Psychotropic drugs 69.60 1.16 0.013 35.09 0.88 0.008
Other drugs 47.58 0.79 0.009 50.86 1.27 0.011
Infusion fluids 465.26 7.75 0.09 430.45 10.76 0.1
Total 451 079 7517.98 100 258 575.5 6464.38 100
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patient. In the XELOX group, in turn, the average cost of 
irradiation per patient was 388.2 PLN.
The cost of medical consultations 
The patients from the FOLFOX4 group had more fre-
quent consultations: in their case, the total number of 
consultations is 680 and, calculated per one person: 11.33, 
whilst in the XELOX group, these figures are 386 and 9.65 
respectively. In both groups, the oncological type of con-
sultation was dominating.
The total cost of medical consultation in the FOLFOX4 
group was 52 810.9 PLN and calculated as per patient 
amounted to 880.18 PLN. The cost of medical consultations 
in the XELOX group is lower, totalling 29 195.6 PLN, and, in 
calculation per patient is 729.89 PLN. The higher costs of 
medical consultations are the result of a higher frequency 
of visits to the oncology and chemotherapy clinics in con-
nection with the administration of cytostatic drugs.
Total costs
Table IV presents the total treatment costs concerning 
the patients with colorectal cancer depending on the ap-
plied treatment protocol.
The total treatment costs of one patient treated with 
the FOLFOX4 protocol amounts to 33 879.13 PLN. In the 
case of the XELOX protocol, this cost is lower, totalling 20 
023.96 PLN. In the FOLFOX4 group, the main share in the 
total cost belongs to hospitalisation costs (60.33%), fol-
lowed by the cost of medication (22.19%) and diagnostic 
procedures (9.17%). In the XELOX group, the dominating 
cost group is made up of the costs of medication (32.3% 
of the total cost). A significant cost is generated by hospi-
talisation, outpatient treatment and diagnostic procedures 
(30.89%, 16.08% and 14. 46% of the total costs respec-
tively). Similarly to the FOLFOX4 protocol, the last share 
in the total costs is made up by the costs of the treatment 
of haematological complications.
Treatments costs and effectiveness 
 The criterion of the evaluation of the efficacy of the two 
alternative chemotherapy regimens (FOLFOX4, XELOX), was 
the average survival period of the patients. As the follow-up 
periods were relatively short, the information concerning 
the patients’ deaths could not be obtained. The evalua-
tion of the therapeutic effects comprised the data from the 
published randomised clinical studies [5–10]. The results 
concerning the average survival period for patients with 
advancement stage III and IV colorectal cancer are collected 
in Table V. 
A longer survival period was observed for patients treat-
ed according to the FOLOFOX4 protocol (27.25 months). In 
the XELOX group, the man survival period was 23.65 months.
The published results of the clinical studies conclude 
that a more effective method of treatment of advancement 
stage III and IV colorectal cancer is chemotherapy with the 
FOLFOX4 regimen.
Incremental costs
In the analysis that was carried out, higher efficacy of 
the FOLFOX4 regimen in the treatment of advancement 
stage III and IV colorectal cancer was proven. The choice 
Table IV. Total cost in the studied groups 
Source Cost (PLN)
FOLFOX4 XELOX
Total cost Average cost per 1 patient % Total cost Average cost per 1 patient %
Hospitalisation 1 226 368.00 20 439.47 60.33 2 474 68.00 6186.70 30.89
Outpatient clinic 33 228.0 553.8 1.64 128790 3219.75 16.08
Diagnostic procedures 1 864 33.80 3107.23 9.17 115 809.20 2895.23 14.46
Drugs 451 079 7517.98 22.19 258 575.5 6464.38 32.3
Haematological complications 460.08 7.67 0.02 528 13.22 0.06
Radiotherapy 82 368 1372.8 4.05 20 592 388.2 2.57
Medical consultations 52 810.9 880.18 2.6 29 195.6 729.89 3.6
Total 2 032 748 33 879.13 100 800 958.3 20 023.96 100
Table V. Average survival period for the patients with III and IV cancer 
advancement stage obtained from clinical studies 
Clinical study Average survival period (months)
FOLFOX4 XELOX
[6] 40.2 37.8
[7] 17.7 18.8
[8] 19.7 –
[9] 31.5 –
[10] – 19.9
[11] – 18.1
Mean value 27.25 23.65
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of the treatment protocol may, however, be decided only 
upon the performance of an incremental analysis. The ob-
jective of the incremental analysis is to determine the ad-
ditional costs, connected with the introduction of the new 
programme and its comparison with the additional result 
obtained thanks to the execution of the new programme. 
The result of the analysis is presented in the form of an in-
cremental cost-effectiveness ratio (ICER), defining the cost 
of obtaining any unit of result once the old programme is 
replaced by a new one or determining the savings from the 
deterioration of the result.
the cost difference between the  
compared methods of treatment
the results difference between  
the compared methods of treatment
In the analysed case, the ICER ratio amounts to the following:
IWEK = 33 879.13 – 20 023.96 (PLN) / 2.27 – 1.97 (years) = 
13 855.04 / 03 = 46 183.47 per year of life
An additional year of life in the case of patients with 
advancement stage III and IV colorectal cancer with the 
application of the longer and more efficient chemotherapy 
regimen “costs” the payer 46 183.47 PLN respectively. 
Sensitivity analysis 
In order to evaluate the influence of the change of the 
key parameters on the final outcome of the analysis, a one-
way sensitivity analysis was performed. All the constituents 
of the direct medical costs were analysed in the scope ± 10 % 
of the core value.
The influence of the change of the key parameters on 
the final result of the analysis depends on the share of the 
specific constituents of the cost in the mean cost per patient. 
Changes in the hospitalisation costs have the largest effect 
on the change of the incremental cost. The parameters 
whose change will significantly affect the total cost com-
prise also the costs of the outpatient visits and the costs 
of medication. The changes of the remaining costs do not 
have any significant effect on the final results of the analysis.
Discussion 
As far as the frequency of incidence is concerned, colo-
rectal cancer occupies a leading position in GI tract tumours. 
In recent years, some improvement of the efficiency of treat-
ment of colorectal cancer has been observed in Poland (the 
rate of 5-year survival is 46% according to the EUROCARE-4 
study). However, in comparison with the countries of West-
ern Europe and the United States of America (5-year survival 
rate — 56.2% and 65.5% respectively) these results are still 
unsatisfactory. The poor treatment results are affected by 
the late diagnosis of the cancer. In about 70% of patients, 
this cancer is diagnosed in the advanced stage, which has 
a bad prognosis (stage III — about 40%, stage IV — about 
30%) [15].
The limited budget of the healthcare system brings 
about the necessity of choosing between treatment proto-
cols with varied efficacy and costs. This choice is assisted by 
pharmacoeconomic analyses which determine the efficacy 
and cost-effectiveness of alternative treatment programmes, 
facilitating rational therapeutic decisions [16]. At the Oncol-
ogy Centre in Bydgoszcz, one of the most frequently used 
treatment programmes has been the FOLFOX4 protocol. At 
the end of 2008, a new programme, XELOX, was introduced. 
In the analysis which was carried out, it was shown that 
FOLFOX4 was the more effective and, at the same time, 
more expensive protocol of systemic treatment of colorectal 
cancer. The average cost of treatment of one patient at stage 
III or IV amounts to 33 879.13 PLN with an average survival 
rate of 2.27 years. In the case of the XELOX protocol, average 
treatment costs for one patient is 20 023.96 PLN with the 
mean survival period is 1.97 years. The efficacy of treatment 
was determined on the basis of the data from clinical studies.
In the XELOX group, the largest share in the total costs 
of the treatment of colorectal cancer in advancement stage 
III and IV at the Oncology Centre in Bydgoszcz was the cost 
of medication (32.3%). In the FOLFOX4 group, the costs 
of medication make up 22.19% of the total costs. In both 
analysed groups, the largest cost of pharmacotherapy is 
generated by the cytostatic drugs: in the XELOX group, 
they make up 99.16%, whilst in the FOLFOX4 group — it is 
99.4% of the total cost of medication. The second largest 
constituent of the total costs in the XELOX group are the 
costs related to the hospitalisation of the patients (30.89%). 
In the FOLFOX4 protocol, hospitalisation is the dominating 
element in the costs (60.33%). The hospitalisation period of 
the patients in the studied groups differs significantly and 
is almost four times longer in the FOLFOX4 protocol. The 
administration of chemotherapy in the FOLFOX4 protocol 
has always been related to almost 3 days of hospital stay. 
In the XELOX protocol, the patients receive cytostatic drugs 
in a one-day hospitalisation. In an outpatient clinic, the 
patients are given oxaliplatin in the form of a 2-hour infu-
sion and oral capecitabine. Hence the cost of the one-day 
hospitalisation in the XELOX group makes up 13.08% of the 
total costs and in the FOLFOX4 only 1.59% of the total cost 
of hospitalisation.
Diagnostic procedures have quite a large share in the 
total costs of the treatment costs (in XELOX — 14.46%, and 
in FOLFOX4 — 9.17%). 
The bibliography presents a few pharmacoeconomic 
studies comparing FOLFOX4 and XELOX. In a Japanese study 
carried out by Shiroiwa et al. the costs and efficiency of the 
treatment of the first and second line of therapy of advanced 
colorectal cancer in FOLFOX4 and XELOX regimens were 
compared. The result of the therapy was defined as the 
ICER = 
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number of days without progression corrected with quality 
(QAPFSD). The study took into consideration only the direct 
medical costs. The analysis has shown that a dominating 
chemotherapy programme in the first and second line of 
treatment is XELOX. This protocol has turned out to be more 
efficient and cost-effective in comparison with FOLFOX4 [5].
A study comparing the costs of treatment of advanced 
colorectal cancer with the FOLFOX4 and XELOX protocol was 
carried out in China. The study was focused on the analysis 
of cost minimisation, with the assumption of comparable 
efficacy of both programmes. The study was carried out 
retrospectively on the basis of the medical history of the pa-
tients treated in two Hongkong hospitals. The direct medical 
and non-medical costs were considered. The analysis has 
shown that treatment with the XELOX protocol is more 
cost-effective [6].
The analysis of the cost minimisation in the treatment 
of patients in stage III of colorectal cancer was carried out 
in Italy (Aitini et al.). This was a retrospective study concern-
ing patients in whom a radical procedure was performed 
and then adjuvant chemotherapy according to FOLFOX4 or 
XELOX protocols was implemented. The study has shown 
that the adjuvant treatment with the XELOX protocol allows 
for a decrease in the therapy cost by about 30% in compari-
son with the FOLFOX4 regimen. The largest share in the total 
treatment costs was made up by the costs related to the hos-
pitalisation and implementation of the chemotherapy port 
(the FOLFOX4 group) or the medication costs (the XELOX 
group). It must be observed that the higher cost of chemo-
therapy based on the use of capecitabine is compensated 
by the savings resulting from the shorter hospitalisation 
period and the oral administration of the drug [7].
Some analogous results were obtained in the analy-
sis of the cost minimisation carried out by Ruiz et al. They 
compared three treatment protocols used in patients with 
colorectal cancer, advancement stage III: FOLFOX4, XELOX 
and FLOX. The study has shown that the smallest cost of 
treatment was generated by the FLOX protocol, whilst the 
highest by FOLFOX4 [8]. 
The above studies have shown that XELOX is the least 
expensive alternative in the treatment of colorectal cancer 
in advancement stage III and IV. The authors also agree that 
the share of chemotherapy and hospitalisation in the total 
treatment cost is quite high. With regards to the high pur-
chasing cost of capecitabine, XELOX is the more expensive 
chemotherapy protocol. This protocol, however, generates 
lower total costs of therapy in comparison with FOLFOX4, on 
account of the shorter hospitalisation period and the smaller 
use of hospital resources by the patients. An analogous cost 
distribution was obtained in this study.
It stems from the published data that the FOLFOX4 
protocol is more effective than the XELOX protocol in the 
treatment of stage III and IV colorectal cancer.
The objective of this work was to compare the costs of 
chemotherapy in FOLFOX4 and XELOX protocols applied in 
the Oncology Centre in Bydgoszcz. The analysis has shown 
that the treatment with the FOLFOX4 protocol is more ex-
pensive and more efficacious. It allows for the prolongation 
of the mean survival period in stage III and IV of colorectal 
cancer by 3.6 months. Incremental costs have been calcu-
lated in order to establish the cost of an additional year of 
life of a patient, with the application of the more expensive 
and more efficacious treatment protocol. This cost totalled 
46 183.47 PLN for each year of life gained. From the point of 
view of the Agency for Health Technology Assessment 
and Tariff System (AOTMiT) the treatment is cost-effective 
because this amount fits between GDP indicators 1 and 3 
per capita. A dominating constituent of the total cost in 
the XELOX group is the cost of medication. The FOLFOX4 
protocol generates higher costs of hospitalisation and ra-
diotherapy. The sensitivity analysis showed that the costs 
of hospitalisation, outpatient care and medication have 
the highest influence on the change of the final outcome.
It must be stressed that the application of chemotherapy 
based on oral capecitabine is undoubtedly related to in-
creased comfort of treatment and a better quality of life. The 
therapy tolerance is good and the oral form of the drug is 
accepted by patients. The mental and physical comfort of 
the patients improves. They are able to lead a normal life. 
Sometimes it is also possible to continue one’s professional 
life. Treatment with the XELOX protocol allows for lowering 
the costs of hospitalisation mainly by means of shortening 
the period of hospital stay in comparison with the FOLFOX4 
protocol. From the patient’s point of view, quality of life 
plays the most important role [17]. It must be pointed out 
that for capecitabine, the period of patent protection has 
expired and there are less expensive generic products on the 
Polish market. Thus, treatment with the XELOX protocol has 
become more cost effective from an economic point of view, 
depending on the patient’s condition and the advancement 
stage of the disease. The main factor which affects the choice 
of specific treatment strategy is its efficacy. The toxicity 
profile and the quality of life are of secondary importance. 
Therefore, the FOLFOX4 chemotherapy protocol remains 
the standard of first line treatment in colorectal cancer in 
advancement stage III and IV.
Conclusions
1. From the two treatment protocols of colorectal cancer 
in advancement stage III and IV, compared above and 
used in the Oncology Centre in Bydgoszcz, the FOLFOX4 
regimen is both more expensive and more efficient.
2. The majority of the total costs of treatment is made up 
by the costs related to the hospitalisation of patients 
(the FOLFOX4 group) and the costs of medication (the 
XELOX group).
476
3. The incremental cost of gaining another year of life with 
the application of the FOLFOX4 protocol, as calculated 
per one patient is 46 183.47 PLN.
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